Patients treated with Odactra experienced a 22% reduction in total combined rhinitis score compared with placebo. The expanded approval was supported by data from a phase 3 trial (ClinicalTrials ...

The U.S. Food and Drug Administration has expanded its indication of Odactra, a house dust mite allergen tablet, for the ...

12 standard quality house dust mite sublingual lyophilisate (SQ-HDM SLIT; Acarizax, ALK-Abello) is indicated 'in adult patients (18-65 years) diagnosed by clinical history and a positive test of house ...

The U.S. Food and Drug Administration has expanded its indication of ALK's Odactra, a house dust mite allergen tablet, for the treatment of house dust mite-induced allergic rhinitis, with or ...

12 SQ-HDM SLIT (standard quality house dust mite sublingual lyophilisate; Acarizax) is available on the NHS as a possible treatment for moderate to severe house dust mite allergic rhinitis in people ...

a house dust mite allergen tablet, for the treatment of house dust mite-induced allergic rhinitis, with or without conjunctivitis, to include children ages 5 through 11 years. Odactra is an ...

WEDNESDAY, March 5, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has expanded its indication of Odactra, a house dust mite allergen tablet, for the treatment of house dust mite ...

ALK (ALKB:DC / OMX: ALK B) today announced that the US Food and Drug Administration (FDA) has approved ALK's ODACTRA® tablet for use in young children with house dust mite (HDM) allergy. ODACTRA® is ...

ALK ( ALKB:DC / OMX: ALK B) today announced that Health Canada has approved ALK’s ACARIZAX ® tablet for use in children, aged five to 11, with house dust mite (HDM) allergy. ACARIZAX ® is now ...

From breaking news to special features, we're on it! Join the NonStop Local Chord group and always be in the know. WEDNESDAY, March 5, 2025 (HealthDay News) -- The U.S. Food and Drug ...